Ye Jintong, Meng Songdong, Zhu Xiaodong
Beijing Combio Pharmaceutical Co., Ltd, Beijing 101111, China.
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Sheng Wu Gong Cheng Xue Bao. 2020 Jan 25;36(1):33-43. doi: 10.13345/j.cjb.190154.
Bispecific antibody (BsAbs) are antibodies (Abs) containing two different antigen-binding sites in one molecule. In the last decade, three BsAbs drugs have been approved for therapeutic use. Meanwhile there are a number of BsAbs in preclinical or clinical studies. In this review, we describe BsAb design, discovery, mechanism of action, and the recent research progress in developing BsAbs.
双特异性抗体（BsAbs）是一种在一个分子中含有两个不同抗原结合位点的抗体（Abs）。在过去十年中，已有三种BsAbs药物被批准用于治疗。与此同时，有许多BsAbs正处于临床前或临床研究阶段。在本综述中，我们描述了BsAb的设计、发现、作用机制以及开发BsAbs的最新研究进展。
